PRODUCT BUZZ

0

LAUNCHES, PROMOTIONS, MERCHANDISING, EVENTS AND OTHER THINGS TO KEEP YOU IN THE KNOW.

ABB OPTICAL GROUP ANNOUNCES FOURTH ANNUAL ABB CARES PROGRAM
ABB Optical Group will begin accepting applications for its fourth annual ABB Cares Program on Monday, Aug 1, 2017. Grants totaling $38,000 will be given to 24 different organizations, one grant of $5,000, two grants of $2,500 and four grants of $1,000 to non-profits nominated by eyecare professionals for improving the quality of life in their respective com-munities. Organizations aren’t required to specialize in eye health in order to qualify. ABBOptical.com/ABBCares

ZERVIATE RECEIVES FDA APPROVAL
The FDA has approved Nicox’s New Drug Application (NDA) for ZERVIATE, a topi-cal ocular formulation of cetirizine that is used to treat the itching associated with al-lergic conjunctivitis. During clinical trials, the drug showed statistically and clinically significantly less ocular itching compared to the placebo at 15 minutes and eight hours post-treatment. Partnering discus-sions are already underway for commer-cialization rights in the U.S. Nicox.com

VITA RISK TEST RECEIVES U.S. MEDICARE APPROVAL
Vita Risk, a pharmacogenetic test launched by ArcticDx in 2013, has been approved for reimbursement by the U.S. Centers for Medicare and Medicaid Services Palmetto Molecular Diagnostic Services Program. Based on an individual’s personal genet-ics, Vita Risk determines which eye vita-min formulation that person should take to maximize benefit and avoid progression to blindness. VitaRisk.com

BAUSCH + LOMB UNVEILS AMD VR
During the annual meeting of the American Optometric Association, held June 21-25 in Washington, DC, Bausch + Lomb announced the launch of its Age-Related Macular Degeneration
(AMD) Virtual Experience. To help optometrists better understand the struggles their patients go through,
the AMD Virtual Experience allows eyecare professionals to experiencethe challenges AMD brings to the estimated 13 million people affected by its mild to more advanced stages. Bausch.com

JOHNSON & JOHNSON VISION CHAMPIONS EYE HEALTH THROUGH ADVOCACY
The latest addition to Johnson & Johnson Vision’s Vision to Action advocacy efforts, Advocacy Academy is an on-demand vir-tual learning tool that uses self-paced mod-ules to educate, empower and mobilize a new community of eye health advocates to engage with lawmakers, agencies and patient associations on key eye health is-sues. The program is designed with gen-erational learning styles in mind, and the modules provide guidance to eye health professionals who are interested in sharing their expertise and insights with lawmak-ers, agencies and associations to effectively advocate for policies that put patients first. JNJVisionCareInfo.com

AOA LAUNCHES HEALTH POLICY INSTITUTE TO ADVANCE PROFESSION
The American Optometric Association (AOA) unveiled the AOA Health Policy In-stitute (HPI), a think tank that will develop evidence-based research, analysis and so-lutions in healthcare policy. HPI plans to use experts from inside and outside the profession to analyze information and evi-dence, and it will use that material to guide policy development. Under the direction of AOA past president Steven A. Loomis, OD, and AOA staff member, Rodney Peele, JD, HPI will look to carry on work started by the National Commission on Vision and Health, a national non-partisan group of public health leaders that works to in-clude access to vision care as part of public health programs. AOA.org/PolicyInstitute

NEWS
For private practice ODs looking to remodel or build a new facility, the first annual National Eyecare Facilities Conference from business consultancy Cleinman Performance Partners will take place October 13-15 at the Crowne Plaza Chicago O’Hare. (BMoore@Cleinman.com)

SynergEyes has named Louise Sclafani, OD, VP of professional affairs.

Jonathan Talamo, MD, joined Johnson & Johnson Vision as chief medical officer and worldwide vice president of medical affairs and clinical affairs.

CLX System is fully integrated to OOGP.

Share.

Leave A Reply